Clinical Trial

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Study acronym: KaiNETIC-3
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
Protocol Amendment History 2 changes
notable Trial sites expanded: 34 -> 53 locations 2026-07-23
notable Trial sites expanded: 25 -> 31 locations 2026-04-29
Trial Details
NCT Number NCT07284979
Lead Sponsor Kailera
Conditions Obesity
Enrollment 1,200 participants
Start Date 2025-12-30
Primary Completion 2028-03 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-22